Radius Health, a US-based developer of drug therapies for osteoporosis and women’s health, plans to sell 6.5 million shares at between $8.50 and $10.50 each in its Nasdaq stock exchange flotation.

Investment banks UBS and Leerink Swann are co-lead underwriters of Radius’ initial public offering (IPO) that will give the company a $283m market capitalisation at $9.50 per share.

Radius Health has raised more than $170m from its venture backers and its shareholders include drugs company Ipsen Pharma.

Radius initially filed for its IPO in February, which was less than two months after closing a $91m series D round.

The major institutional shareholders in Radius are private equity firm MPM Capital (which holds 39.2% of Radius’ shares), medical foundation the Wellcome Trust (13.4%), venture capital firms Healthcare Ventures (10.7%), Saints Capital (8.7%), Oxford Bioscience Partners (6.4%), investment firm BB Biotech (8.9%), Biotech Growth (5.7%) and Brookside Capital Partners (5.7%),…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?